Home » Authors » Kim Coghill

Articles by Kim Coghill

Hybridon Raises $14.6M Privately To Fund Pipeline Development

Sep. 3, 2003

GPC Biotech Moves Satraplatin Into Phase III Registration Trial

Sep. 3, 2003

GPC Biotech Moves Satraplatin Into Phase III Registration Trial

Sep. 3, 2003

Hybridon Raises $14.6M Privately To Fund Pipeline Development

Sep. 3, 2003

Government Considers Changes To Medicare Reimbursement

Sep. 2, 2003

Government Considers Changes To Medicare Reimbursement

Sep. 2, 2003

Myogen Raises $40M Privately, Then Registers For $70M IPO

Aug. 29, 2003

Falling in step with others in the industry, Myogen Inc. Thursday afternoon said it registered for an initial public offering, estimating it would raise $75 million. (BioWorld Today)

Myogen Raises $40M Privately, Then Registers For $70M IPO

Aug. 29, 2003

Falling in step with others in the industry, Myogen Inc. Thursday afternoon said it registered for an initial public offering, estimating it would raise $75 million. (BioWorld Today)

Metabolex Privately Raises $27M For MBX-102 Phase II Program

Aug. 28, 2003

Metabolex Privately Raises $27M For MBX-102 Phase II Program

Aug. 28, 2003

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 7, 2026.
CINP 2026: Prenatal and adolescent stress shape brain vulnerability
BioWorld Science
Human biology is extraordinarily complex, and that sophistication emerges from the very beginning. During embryonic and fetal development, the organism’s...
Hyperexcitability may be joint problem in epilepsy, dementia
BioWorld
The majority of epilepsies are developmental disorders that start in childhood. But there is a large minority that starts in late adulthood. And increasingly,...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
‘Target-high but uptake-defective’ state identified in ADC resistance
BioWorld
Separate research teams have reported new insights into resistance mechanisms to the antibody-drug conjugate (ADC) Padcev (enfortumab vedotin, Astellas Pharma...